ARGX-117
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Multifocal Motor Neuropathy (MMN)
Conditions
Multifocal Motor Neuropathy (MMN)
Trial Timeline
Jan 18, 2023 → Sep 30, 2029
NCT ID
NCT05405361About ARGX-117
ARGX-117 is a phase 2 stage product being developed by Argenx for Multifocal Motor Neuropathy (MMN). The current trial status is active. This product is registered under clinical trial identifier NCT05405361. Target conditions include Multifocal Motor Neuropathy (MMN).
What happened to similar drugs?
0 of 1 similar drugs in Multifocal Motor Neuropathy (MMN) were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05907096 | Phase 2 | Active |
| NCT05405361 | Phase 2 | Active |
| NCT05225675 | Phase 2 | Completed |
Competing Products
7 competing products in Multifocal Motor Neuropathy (MMN)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfuvirtide + Tenofovir-Emtricitabine | Roche | Phase 2 | 35 |
| Vivaglobin | CSL | Phase 2 | 35 |
| Empasiprubart + IVIG (Intravenous Immunoglobulin) | Argenx | Phase 3 | 44 |
| ARGX-117 | Argenx | Phase 2 | 32 |
| mefloquine | Biogen | Phase 1/2 | 21 |
| Tysabri | Biogen | Pre-clinical | 23 |
| HyQvia + Subcuvia | Baxter | Phase 2 | 32 |